| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $25.6M | — | +19.0% |
| SG&A Expense | $7.6M | — | +43.8% |
| Operating Income | -$33.2M | — | -23.9% |
| Net Income | -$32.6M | — | -27.9% |
| EPS (Basic) | -$1.08 | — | -332.0% |
| EPS (Diluted) | -$1.08 | — | -332.0% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $186.6M | +1105.4% | +1204.7% |
| Current Assets | $188.8M | +725.4% | +894.8% |
| Total Assets | $189.7M | +688.9% | +824.9% |
| Current Liabilities | $38.4M | +25.3% | +49.9% |
| Total Liabilities | $38.5M | +25.3% | +49.2% |
| Stockholders' Equity | $151.2M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$17.3M | — | +20.6% |
| Capital Expenditures | $2K | — | -95.7% |
| Investing Cash Flow | -$2K | — | +95.7% |
| Financing Cash Flow | $188.6M | — | — |
| Free Cash Flow | -$17.3M | — | +20.7% |
| +2960.5% |